Atractylenolide III

Research use only, not for human use.

Atractylenolide III may have therapeutic potential in treating homocysteine-mediated cognitive impairment and neuronal injury.

Atractylenolide III may have therapeutic potential in treating homocysteine-mediated cognitive impairment and neuronal injury. Atractylenolide III is a potential candidate for the treatment of human lung carcinoma by inducing the release of cytochrome c, upregulating the expression of Bax and translocating apoptosis-inducing factor.

Western Blot Analysis Cell Line:A549 Concentration:1, 10, 100 μM Incubation Time:24 h, 48 h Result:Increased active form of caspase-9, caspase-3, and the cleavage of PARP at 48 h.Increased the expression of proapoptotic protein bax, and induced AIF translocation to the nucleus at 24 h.

Animal Model:70% ethanol-induced gastric ulcers in rats Dosage:5 and 10 mg/kg Administration:p.o.Result:Inhibited gastric ulcer formation and the necrotic erosion of gastric mucosa.Downregulated the MMP-2/9 expression by activating the TIMP-2 and TIMP-1 expressions.

ICodonolactone | 8β-Hydroxyasterolide

Others

Other Targets

Apoptosis inducer

Cancer

——

73030-71-4

248.32

C15H20O3

>98% (HPLC)

DMSO : ≥ 100 mg/mL; 402.71 mM

C=C1CCC[C@]2([C@H]1CC1=C(C)C(=O)O[C@]1(C2)O)C

——

(-20℃)

With Ice Pack

≥ 2 years